Clinical Trial

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

Study acronym: PRISM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the various aspects of treatment effectiveness of \[177Lu\]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings. The study will be conducted using real-world data sources from the United States (US) and Germany.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-10-31 -> 2027-01-31 2026-07-23
minor Completion pushed: 2026-10-31 -> 2027-01-31 2026-07-23
Trial Details
NCT Number NCT07697989
Lead Sponsor Novartis Pharmaceuticals
Conditions Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis
Enrollment 1,085 participants
Start Date 2026-10-15
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22